Literature DB >> 22015493

Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.

Ying Wang1, Min Gu, Yingchang Mi, Lugui Qiu, Shougeng Bian, Jianxiang Wang.   

Abstract

Knowledge of mixed phenotype acute leukemia (MPAL) with t(9;22)(q34;q11.2) and/or bcr-abl (Ph-positive MPAL) is limited. In this report, we review 21 adult patients with Ph-positive and/or bcr-abl positive MPAL. They were predominantly male, and presented with high WBC counts; 61.9% patients had WBC counts higher than 30 × 10(9)/L, and 33.3% patients had WBC counts higher than 100 × 10(9)/L. Electron microscopy (EM)-determined positivity for myeloperoxidase (MPO) should be considered for the classification of acute leukemia because MPO was positive by EM and flow cytometry only in 14.3% of cases in our study. Six cases (30.0%) had additional chromosome aberrations. Expression of p190(bcr-abl) was more common than that of p210(bcr-abl). There was no difference in characteristics between the p190(bcr-abl) positive and p210(bcr-abl) positive groups. The overall complete remission (CR) rate was 81.0%. Females, and patients with high WBC (>100 × 10(9)/L) at baseline had lower CR rate (57.1, 57.1%, respectively). The treatment outcome of Ph-positive MPAL is poor; the 1-year overall survival (OS) and relapse-free survival (RFS) rate were 28.0 and 18.0%, respectively. Imatinib and allogeneic hematopoietic stem cell transplantation can improve survival with Ph-positive MPAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015493     DOI: 10.1007/s12185-011-0953-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system.

Authors:  T M Owaidah; A Al Beihany; M A Iqbal; N Elkum; G T Roberts
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

2.  Outcome of biphenotypic acute leukemia.

Authors:  S Killick; E Matutes; R L Powles; M Hamblin; J Swansbury; J G Treleaven; A Zomas; A Atra; D Catovsky
Journal:  Haematologica       Date:  1999-08       Impact factor: 9.941

3.  [Study on the clinical characteristics of adult biphenotypic acute leukaemia].

Authors:  Jing Zhang; Ying-Chang Mi; Ying Wang; Dong Lin; Wei Li; Xiao-Ming Sun; Kang Zhou; Shou-Geng Bian; Jian-Xiang Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2009-01

4.  Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.

Authors:  Yenan Li; Dehui Zou; Yaozhong Zhao; Yingchang Mi; Jianxiang Wang; Lugui Qiu
Journal:  Leuk Lymphoma       Date:  2010-03

5.  Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.

Authors:  Estella Matutes; Winfried F Pickl; Mars Van't Veer; Ricardo Morilla; John Swansbury; Herbert Strobl; Andishe Attarbaschi; Georg Hopfinger; Sue Ashley; Marie Christine Bene; Anna Porwit; Alberto Orfao; Petr Lemez; Richard Schabath; Wolf-Dieter Ludwig
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

Review 6.  Mixed-phenotype acute leukemia: historical overview and a new definition.

Authors:  O K Weinberg; D A Arber
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

7.  Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  K-H Lee; J-H Lee; S-J Choi; J-H Lee; M Seol; Y-S Lee; W-K Kim; J-S Lee; E-J Seo; S Jang; C-J Park; H-S Chi
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

8.  Clinical characteristics and outcome of children with biphenotypic acute leukemia.

Authors:  Amal S Al-Seraihy; Tarek M Owaidah; Mouhab Ayas; Hassan El-Solh; Mohammed Al-Mahr; Ali Al-Ahmari; Asim F Belgaumi
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

9.  Immunological and ultrastructural studies in acute biphenotypic leukaemia.

Authors:  V Shetty; A Chitale; E Matutes; V Buccheri; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

10.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).

Authors:  M C Bene; G Castoldi; W Knapp; W D Ludwig; E Matutes; A Orfao; M B van't Veer
Journal:  Leukemia       Date:  1995-10       Impact factor: 11.528

  10 in total
  10 in total

1.  Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.

Authors:  S Couban; L Savoie; Y Abou Mourad; B Leber; M Minden; R Turner; V Palada; N Shehata; A Christofides; S Lachance
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

2.  Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.

Authors:  K E Hayes; E L Walk; A G Ammer; L C Kelley; K H Martin; S A Weed
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

3.  Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.

Authors:  Eman O Rasekh; Randa Osman; Dalia Ibraheem; Youssef Madney; Enas Radwan; Abdallah Gameel; Ahmed Abdelhafiz; Azza Kamel; Sally Elfishawi
Journal:  Ann Hematol       Date:  2020-11-23       Impact factor: 3.673

4.  Hypocellular Philadelphia chromosome-positive mixed-phenotype acute leukemia successfully treated with dasatinib: A case report.

Authors:  Shin Lee; Kei Fujita; Hiroto Wakayama; Yusuke Kito; Takeshi Hara; Hisashi Tsurumi
Journal:  Mol Clin Oncol       Date:  2021-12-14

5.  Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.

Authors:  Chika Kawajiri; Hiroaki Tanaka; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Toshiyuki Takagi; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Naomi Shimizu; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2014-02-15       Impact factor: 2.490

6.  A Study on the Expression of BCR-ABL Transcript in Mixed Phenotype Acute Leukemia (MPAL) Cases Using the Reverse Transcriptase Polymerase Reaction Assay (RT-PCR) and its Correlation with Hematological Remission Status Post Initial Induction Therapy.

Authors:  Prateek Bhatia; Jogeshwar Binota; Neelam Varma; Deepak Bansal; Amita Trehan; Ram Kumar Marwaha; Pankaj Malhotra; Subhash Varma
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-05-08       Impact factor: 2.576

7.  High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia.

Authors:  Ciera L Patzke; Ashkan Emadi
Journal:  Am J Leuk Res       Date:  2020-10-15

Review 8.  The Philadelphia chromosome in leukemogenesis.

Authors:  Zhi-Jie Kang; Yu-Fei Liu; Ling-Zhi Xu; Zi-Jie Long; Dan Huang; Ya Yang; Bing Liu; Jiu-Xing Feng; Yu-Jia Pan; Jin-Song Yan; Quentin Liu
Journal:  Chin J Cancer       Date:  2016-05-27

9.  Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.

Authors:  Binbin Lai; Qitian Mu; Huiling Zhu; Yi Wang; Yi Zhang; Kaihong Xu; Lixia Sheng; Guifang Ouyang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

10.  [Haploid hematopoietic stem cell transplantation in the treatment of Ph chromosome positive mixed phenotype acute leukemia: report of two cases with literature review].

Authors:  T T Li; H Ai; Q Wang; Y W Fu; X D Wei; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.